Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BEZAWIT TEKOLA

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1770742595
CMS profile
1304623
Location
FAIRFAX, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,039.04

76 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,039.04 76

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 76 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BEZAWIT TEKOLA

NPI 1770742595 · CMS profile ID 1304623

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

FAIRFAX, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 76 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1770742595?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BEZAWIT TEKOLA, NPI 1770742595, CMS profile ID 1304623. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 76 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1770742595?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). BEZAWIT TEKOLA, NPI 1770742595, CMS profile ID 1304623. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 76 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1770742595?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
BEZAWIT TEKOLA, NPI 1770742595, CMS profile ID 1304623, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 76 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1770742595?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

76 matching records · $1,039.04 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 76 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 76.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $17.0812/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681615117 CMS
Takeda Pharmaceuticals U.S.A., Inc. $11.3712/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682074665 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $8.2512/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684956377 CMS
Gilead Sciences, Inc. $13.5211/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681615113 CMS
Gilead Sciences, Inc. $13.5211/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681615115 CMS
PFIZER INC. $20.2911/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673728987 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.6411/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682007345 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.8911/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681694749 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $8.2611/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684956375 CMS
PFIZER INC. $18.3311/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673687509 CMS
Merck Sharp & Dohme Corporation $14.6311/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695828467 CMS
Janssen Biotech, Inc. $17.8910/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658749047 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.8710/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684956373 CMS
AbbVie, Inc. $20.3010/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648298247 CMS
AbbVie, Inc. $0.7710/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648298251 CMS
AbbVie, Inc. $1.3610/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648298243 CMS
Gilead Sciences, Inc. $14.3310/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681615111 CMS
AbbVie, Inc. $21.2710/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648298245 CMS
AbbVie, Inc. $1.3510/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648298255 CMS
Takeda Pharmaceuticals U.S.A., Inc. $11.3410/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681762089 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.6510/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682049839 CMS
Gilead Sciences, Inc. $15.8610/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681615109 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.8509/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684956371 CMS
PFIZER INC. $16.8009/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672810271 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.2409/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681685523 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.7409/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681690971 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1.2309/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681853385 CMS
AbbVie, Inc. $1.1909/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648298233 CMS
AbbVie, Inc. $17.7509/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648298239 CMS
AbbVie, Inc. $22.5509/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648298237 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.7508/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681743711 CMS
AbbVie, Inc. $21.9208/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648298219 CMS
AbbVie, Inc. $1.0408/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648298221 CMS
QOL Medical, LLC $12.4808/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637744271 CMS
Ironwood Pharmaceuticals, Inc $11.1008/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709213677 CMS
PFIZER INC. $23.7908/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672575543 CMS
UCB, Inc. $19.3808/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688325955 CMS
Janssen Biotech, Inc. $14.6607/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658749043 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $6.5507/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684956367 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $2.2207/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684956369 CMS
Gilead Sciences, Inc. $15.8607/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681615107 CMS
UCB, Inc. $20.6007/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688309477 CMS
PFIZER INC. $20.2607/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672301687 CMS
Ironwood Pharmaceuticals, Inc $12.0407/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709213679 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.4407/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684956365 CMS
UCB, Inc. $16.1307/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688293153 CMS
AbbVie, Inc. $17.2806/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648298199 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $21.6506/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684956363 CMS
AbbVie, Inc. $19.0806/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648298195 CMS
AbbVie, Inc. $0.9906/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648298197 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,039.04 76
PY2020 $454.06 31
PY2021 $513.43 28
PY2022 $1,500.48 85
PY2023 $1,316.10 76
PY2024 $1,422.82 66
PY2025 $1,986.18 89

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $63.82 1
PY2024 Principal investigator $814.08 1
PY2023 Principal investigator $33,698.06 8
PY2022 Principal investigator $83,729.01 12
PY2021 Principal investigator $46,132.10 21
PY2020 Principal investigator $113,515.53 46
PY2019 Principal investigator $119,167.67 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Gilead Sciences, Inc. $1,370.00 10/20/2021 Non-covered Recipient Entity
VERITY RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803532315
Principal investigator 1 Gilead Sciences, Inc. $52.00 08/18/2021 Non-covered Recipient Entity
VERITY RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803532313
Principal investigator 1 Gilead Sciences, Inc. $1,370.00 07/21/2021 Non-covered Recipient Entity
VERITY RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803532311
Principal investigator 1 Allergan, Inc. $2,551.15 06/24/2021 Non-covered Recipient Entity
VERITY RESEARCH INC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789000673
Principal investigator 1 Gilead Sciences, Inc. $1,704.00 06/23/2021 Non-covered Recipient Entity
VERITY RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803532309
Principal investigator 1 PFIZER INC. $10.00 06/23/2021 Non-covered Recipient Entity
Verity Research Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF06865571 DGAT2I ALONE AND WHEN COADMINISTERED WITH PF05221304 ACCI IN ADULT PARTICIPANTS WITH BIOPSYCONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3 No dispute reported 06/30/2026 832710705
Principal investigator 1 Braintree Laboratories, Inc. $1,500.00 06/14/2021 Non-covered Recipient Entity
VERITY RESEARCH INC
BLI4900-302 No dispute reported 06/30/2026 805281392
Principal investigator 1 Braintree Laboratories, Inc. $2,887.00 06/14/2021 Non-covered Recipient Entity
VERITY RESEARCH INC
BLI4900-302 No dispute reported 06/30/2026 805281399
Principal investigator 1 Braintree Laboratories, Inc. $90.00 05/21/2021 Non-covered Recipient Entity
VERITY RESEARCH INC
BLI4900-302 No dispute reported 06/30/2026 805280599
Principal investigator 1 PFIZER INC. $160.30 05/12/2021 Non-covered Recipient Entity
Verity Research Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF06865571 DGAT2I ALONE AND WHEN COADMINISTERED WITH PF05221304 ACCI IN ADULT PARTICIPANTS WITH BIOPSYCONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3 No dispute reported 06/30/2026 832887797
Principal investigator 1 Allergan, Inc. $1,945.25 05/01/2021 Non-covered Recipient Entity
VERITY RESEARCH INC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789000671
Principal investigator 1 Gilead Sciences, Inc. $1,315.00 04/26/2021 Non-covered Recipient Entity
VERITY RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803532307
Principal investigator 1 Allergan, Inc. $1,818.30 04/22/2021 Non-covered Recipient Entity
VERITY RESEARCH INC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789000669
Principal investigator 1 Gilead Sciences, Inc. $252.00 03/17/2021 Non-covered Recipient Entity
VERITY RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803532305
Principal investigator 1 Braintree Laboratories, Inc. $4,466.70 03/12/2021 Non-covered Recipient Entity
VERITY RESEARCH INC
BLI4900-302 No dispute reported 06/30/2026 805279881
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,700.00 03/10/2021 Non-covered Recipient Entity
VERITY RESEARCH
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 826488599
Principal investigator 1 PFIZER INC. $2,197.00 02/24/2021 Non-covered Recipient Entity
Verity Research Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF06865571 DGAT2I ALONE AND WHEN COADMINISTERED WITH PF05221304 ACCI IN ADULT PARTICIPANTS WITH BIOPSYCONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3 No dispute reported 06/30/2026 832890621
Principal investigator 1 Gilead Sciences, Inc. $8,922.00 02/22/2021 Non-covered Recipient Entity
VERITY RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803532303
Principal investigator 1 Gilead Sciences, Inc. $4,660.00 02/17/2021 Non-covered Recipient Entity
VERITY RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803532301
Principal investigator 1 Braintree Laboratories, Inc. $5,126.40 01/29/2021 Non-covered Recipient Entity
VERITY RESEARCH INC
BLI4900-302 No dispute reported 06/30/2026 805279487
Principal investigator 1 Allergan, Inc. $35.00 01/14/2021 Non-covered Recipient Entity
VERITY RESEARCH INC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 789000667